WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1998002434) FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/1998/002434 International Application No.: PCT/EP1997/003672
Publication Date: 22.01.1998 International Filing Date: 11.07.1997
Chapter 2 Demand Filed: 09.01.1998
IPC:
C07D 401/04 (2006.01) ,C07D 403/04 (2006.01) ,C07D 403/14 (2006.01) ,C07D 405/04 (2006.01) ,C07D 405/14 (2006.01) ,C07D 409/04 (2006.01) ,C07D 413/04 (2006.01) ,C07D 413/14 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
405
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
405
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
409
Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14
containing three or more hetero rings
Applicants: COCKERILL, George, Stuart[GB/GB]; GB (UsOnly)
CARTER, Malcolm, Clive[GB/GB]; GB (UsOnly)
GUNTRIP, Stephen, Barry[GB/GB]; GB (UsOnly)
SMITH, Kathryn, Jane[GB/GB]; GB (UsOnly)
GLAXO GROUP LIMITED[GB/GB]; Glaxo Wellcome House Berkeley Avenue Greenford Middlesex UB6 0NN, GB (AllExceptUS)
Inventors: COCKERILL, George, Stuart; GB
CARTER, Malcolm, Clive; GB
GUNTRIP, Stephen, Barry; GB
SMITH, Kathryn, Jane; GB
Agent: REED, Michael, A.; Glaxo Wellcome plc Glaxo Wellcome House Berkeley Avenue Greenford, Middlesex UB6 0NN, GB
Priority Data:
9614755.813.07.1996GB
9625458.607.12.1996GB
Title (EN) FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
(FR) COMPOSES HETEROCYCLIQUES CONDENSES EN TANT QU'INHIBITEURS DE LA PROTEINE TYROSINE KINASE
Abstract:
(EN) Substituted heteroaromatic compounds of formula (I) and in particular substituted quinolines and quinazolines, are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of cancer and psoriasis, or a salt or solvate thereof; wherein X is N or CH; Y is a group W(CH2), (CH2)W, or W, in which W is O, S(O)m wherein m is 0, 1 or 2, or NRa wherein Ra is hydrogen or a C1-8 alkyl group; R1 represents a phenyl group or a 5- or 6-membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S(O)m, wherein m is as defined above, with the provisos that the ring does not contain two adjacent O or S(O)m atoms and that where the ring contains only N as heteroatom(s) the ring is C-linked to the quinazoline or quinoline ring, R1 being optionally substituted by one or more R3 groups; P = 0 to 3; U, R2, R3 are as defined in the application.
(FR) L'invention a trait à des composés hétéroaromatiques substitués de la formule (I), et en particulier à des quinoléines et quinazolines substituées, qui sont des inhibiteurs de la protéine tyrosine kinase. Les composés sont décrits, ainsi que leurs procédés de préparation, des compositions pharmaceutiques contenant de tels composés et leur utilisation médicale, par exemple dans le traitement du cancer et du psoriasis; ou un sel ou un solvate de celui-ci, où X est N ou CH, Y est un groupe W(CH2), (CH2)W, ou W, dans lequel W est O, S(O)m où m a pour valeur 0, 1 ou 2, ou NRa où Ra est de l'hydrogène ou un groupe alkyle C1-8. R1 représente un groupe phényle ou un noyau hétérocyllique à 5 ou 6 chaînons contenant de 1 à 4 hétéroatomes sélectionnés parmi N, O, S(O)m, où m est tel que défini plus haut, à condition que ce noyau ne conteinne pas deux atomes O ou S(O)m adjacents, et que lorsque ce noyqu ne contient que N comme hétéroatome(s), il soit lié au noyau quinazoline ou quinoline par un atome de C, R1 étant substitué optionnellement par un ou plusieurs groupes R3; P = 0 à 3, U, R2, R3 sont tels que définis dans le dossier.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)